Drug Profile

Research programme: biosimilars - Lupin

Alternative Names: Teriparatide biosimilar - Lupin

Latest Information Update: 28 Jun 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lupin
Class Monoclonal antibodies; Recombinant fusion proteins; Recombinant proteins
Mechanism of Action Tumour necrosis factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

No development reported Inflammation; Rheumatoid arthritis; Viral infections

28 Jun 2018 No recent reports of development identified for preclinical development in Viral-infections in India
28 May 2018 No recent reports of development identified for preclinical development in Inflammation in India (SC, Injection)
28 May 2018 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in India (SC, Injection)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com